Progress on the efficacy and potential mechanisms of rapamycin in the treatment of immune thrombocytopenia

References

• Zahidin MA, Mohd Noor NH, Johan MF, et al. A review on secondary immune thrombocytopenia in Malaysia. Healthcare (Basel). 2022;10:38.
   Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–2393.
   PubMed Web of Science ®Google Scholar
• Liu XG, Bai XC, Chen FP, et al. Chinese guidelines for treatment of adult primary immune thrombocytopenia. Int J Hematol. 2018;107:615–623.
   PubMed Web of Science ®Google Scholar
• Feng Y, Quan Y, Cassady K, et al. Clinical characteristics in immune thrombocytopenia patients after COVID-19 vaccination. Hum Vaccin Immunother. 2022;7:2119043. doi:10.1080/21645515.2022.2119043.
   Google Scholar
• Kim DS. Recent advances in treatments of adult immune thrombocytopenia. Blood Res. 2022;57:S112–S119.
   PubMed Web of Science ®Google Scholar
• Boyle S, White RH, Brunson A, et al. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood. 2013;121:4782–4790.
   PubMed Web of Science ®Google Scholar
• Miltiadous O, Hou M, Bussel JB. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood. 2020;135:472–490.
   PubMed Web of Science ®Google Scholar
• Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3:3780–3817.
   PubMed Web of Science ®Google Scholar
• Lv Y, Shi H, Liu H, et al. Current therapeutic strategies and perspectives in refractory ITP: what have we learned recently? Front Immunol. 2022;13:953716.
   PubMed Web of Science ®Google Scholar
• Yu J, Xu Z, Zhuo Y, et al. Development and validation of a nomogram for steroid-resistance prediction in immune thrombocytopenia patients. Hematology. 2021;26:956–963.
   PubMed Web of Science ®Google Scholar
• Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol. 2010;47:187–198.
   PubMed Web of Science ®Google Scholar
• Horikoshi A, Tsukuda J, Abe R, et al. Development of myelofibrosis during eltrombopag treatment in a patient with immune thrombocytopenia. Rinsho Ketsueki. 2016;57:638–641.
   PubMedGoogle Scholar
• Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130:2527–2536.
   PubMed Web of Science ®Google Scholar
• Ghanima W, Geyer JT, Lee CS, et al. Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up. Haematologica. 2014;99:937–944.
   PubMed Web of Science ®Google Scholar
• Wong RSM, Khelif A, Salama A, et al. Occurrence and management of cataracts in adult patients (PTS) with chronic immune thrombocytopenia (cITP) during long-term treatment with eltrombopag (EPAG): results from the extend study. Blood. 2017;130.
   Web of Science ®Google Scholar
• Janku F. Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: from laboratory to patients. Cancer Treat Rev. 2017;59:93–101.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang R. Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs. Drug Test Anal. 2018;10:81–94.
   PubMed Web of Science ®Google Scholar
• Hua H, Kong Q, Zhang H, et al. Targeting mTOR for cancer therapy. J Hematol Oncol. 2019;12:71.
   PubMed Web of Science ®Google Scholar
• Linke M, Fritsch SD, Sukhbaatar N, et al. mTORC1 and mTORC2 as regulators of cell metabolism in immunity. FEBS Lett. 2017;591:3089–3103.
   PubMed Web of Science ®Google Scholar
• Li HL, Deng NH, He XS, et al. Small biomarkers with massive impacts: PI3K/AKT/mTOR signalling and microRNA crosstalk regulate nasopharyngeal carcinoma. Biomark Res. 2022;10:52.
   PubMed Web of Science ®Google Scholar
• Fuhler GM, Tyl MR, Olthof SG, et al. Distinct roles of the mTOR components rictor and raptor in MO7e megakaryocytic cells. Eur J Haematol. 2009;83:235–245.
   PubMed Web of Science ®Google Scholar
• Webster AC, Lee VW, Chapman JR, et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation. 2006;81:1234–1248.
   PubMed Web of Science ®Google Scholar
• Al-Hammadi S, Almarzooqi S, Albawardi A, et al. Effects of molecularly targeted therapies on murine thymus: highly selective mTOR inhibitors induce reversible thymic involution. Exp Hematol Oncol. 2015;5:22.
   PubMedGoogle Scholar
• Feng YM, Xiao YS, Yan HJ, et al. Sirolimus as rescue therapy for refractory/relapsed immune thrombocytopenia: results of a single-center, prospective, single-arm study. Front Med (Lausanne). 2020;7:110. doi:10.3389/fmed.2020.00110.
   PubMed Web of Science ®Google Scholar
• Hongju Y, Ping W, Yao Q, et al. Clinical efficacy of sirolimus in treatment of relapsed and refractory autoimmune hemolytic anemia in adults. J Third Mil Med Univ. 2020;42:1757–1762. [in Chinese].
   Google Scholar
• Zhu W, Feng YM, Chen T, et al. The clinical observation of sirolimus combined with calcineurin inhibitors for steroid-resistant/steroid-dependent extensive cGVHD. Zhonghua Xue Ye Xue Za Zhi. 2020;41:716–722.
   PubMedGoogle Scholar
• Feng Y, Chen X, Cassady K, et al. The role of mTOR inhibitors in hematologic disease: from bench to bedside. Front Oncol. 2021;10:611690.
   PubMed Web of Science ®Google Scholar
• Li J, Wang Z, Dai L, et al. Effects of rapamycin combined with low dose prednisone in patients with chronic immune thrombocytopenia. Clin Dev Immunol. 2013;2013:548085.
   PubMedGoogle Scholar
• Jasinski S, Weinblatt ME, Glasser CL. Sirolimus as an effective agent in the treatment of immune thrombocytopenia (ITP) and Evans Syndrome (ES): a single institution's experience. J Pediatr Hematol Oncol. 2017;39:420–424.
   PubMed Web of Science ®Google Scholar
• Li HM, Ji J, Du YL, et al. Sirolimus is effective for primary relapsed/refractory autoimmune cytopenia: a multicenter study. Exp Hematol. 2020;89:87–95.
   PubMed Web of Science ®Google Scholar
• Mousavi-Hasanzadeh M, Bagheri B, Mehrabi S, et al. Sirolimus versus cyclosporine for the treatment of pediatric chronic immune thrombocytopenia: a randomized blinded trial. Int Immunopharmacol. 2020;88:106895.
   PubMed Web of Science ®Google Scholar
• Li Q, Kang HY, Fan L, et al. Clinical study on calcitriol combined with sirolimus in the treatment of chronic primary immune thrombocytopenia patients. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021;29:1911–1916.
   PubMedGoogle Scholar
• Miano M. How I manage Evans Syndrome and AIHA cases in children. Br J Haematol. 2016;172:524–534.
   PubMed Web of Science ®Google Scholar
• Niss O, Sholl A, Bleesing JJ, et al. IL-10/Janus kinase/signal transducer and activator of transcription 3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndrome. J Allergy Clin Immunol. 2015;135:762–770.
   PubMed Web of Science ®Google Scholar
• Consonni F, Gambineri E, Favre C. ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies. Ann Hematol. 2022;101:469–484.
   PubMed Web of Science ®Google Scholar
• Gu H, Chen Z, Ma J, et al. Sirolimus is effective in autoimmune lymphoproliferative syndrome-type III: a pedigree case report with homozygous variation PRKCD. Int J Immunopathol Pharmacol. 2021;35:20587384211025934.
   PubMed Web of Science ®Google Scholar
• Bride KL, Vincent T, Smith-Whitley K, et al. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016;127:17–28.
   PubMed Web of Science ®Google Scholar
• Gu H, Ma J, Chen Z, et al. Synergistic defects of novo FAS and homozygous UNC13D leading to autoimmune lymphoproliferative syndrome-like disease: a 10-year-old Chinese boy case report. Gene. 2018;672:45–49.
   PubMed Web of Science ®Google Scholar
• Nocerino A, Valencic E, Loganes C, et al. Low-dose sirolimus in two cousins with autoimmune lymphoproliferative syndrome-associated infection. Pediatr Int. 2018;60:315–317.
   PubMed Web of Science ®Google Scholar
• Lai ZW, Kelly R, Winans T, et al. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. Lancet. 2018;391:1186–1196.
   PubMed Web of Science ®Google Scholar
• Wu C, Wang Q, Xu D, et al. Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial. Rheumatology (Oxford). 2021;60:2629–2634.
   PubMed Web of Science ®Google Scholar
• Shah M, Edman MC, Reddy Janga S, et al. Rapamycin eye drops suppress lacrimal gland inflammation In a murine model of Sjögren's syndrome. Invest Ophthalmol Vis Sci. 2017;58:372–385.
   PubMed Web of Science ®Google Scholar
• Xie W, Ji L, Zhang Z. Sirolimus monotherapy for thrombocytopenia in primary antiphospholipid syndrome: a pilot study from a tertiary referral center. Front Immunol. 2022;13:857424.
   PubMed Web of Science ®Google Scholar
• Xing L, Wang Y, Liu H, et al. Case report: sirolimus alleviates persistent cytopenia after CD19 CAR-T-cell therapy. Front Oncol. 2021;11:798352.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Saitoh T, Gotoh N, et al. The cytokine polymorphisms affecting Th1/Th2 increase the susceptibility to, and severity of, chronic ITP. BMC Immunol. 2017;18:26.
   PubMed Web of Science ®Google Scholar
• Zufferey A, Kapur R, Semple JW. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med. 2017;6:16.
   PubMed Web of Science ®Google Scholar
• Manning BD. Game of TOR — the target of rapamycin rules four kingdoms. N Engl J Med. 2017;377:1297–1299.
   PubMed Web of Science ®Google Scholar
• Stallone G, Infante B, Di Lorenzo A, et al. mTOR inhibitors effects on regulatory T cells and on dendritic cells. J Transl Med. 2016;14:152.
   PubMed Web of Science ®Google Scholar
• Song X, Gao J, Liu H, et al. Rapamycin alleviates renal damage in mice with systemic lupus erythematosus through improving immune response and function. Biomed Pharmacother. 2021;137:111289.
   PubMed Web of Science ®Google Scholar
• Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: standard treatment and systematic review of alternative treatments. World J Gastroenterol. 2017;23:6030–6048.
   PubMed Web of Science ®Google Scholar
• Yu Y, Hou Y, Zhao Y, et al. Platelet autoantibody specificity and response to rhTPO treatment in patients with primary immune thrombocytopenia. Br J Haematol. 2021;194:191–194.
   PubMed Web of Science ®Google Scholar
• Zhang HY, Hou M, Zhang XH, et al. The diagnostic value of platelet glycoprotein-specific autoantibody detection in idiopathic thrombocytopenic purpura. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2004;12:204–206.
   PubMedGoogle Scholar
• Zhu XJ, Shi Y, Peng J, et al. The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia. Blood. 2009;114:5362–5367.
   PubMed Web of Science ®Google Scholar
• Zeng Q, Qin S, Zhang H, et al. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells. J Cell Physiol. 2018;233:516–529.
   PubMed Web of Science ®Google Scholar
• Zeng Q, Zhou Z, Qin S, et al. Rapamycin inhibits B-cell activating factor (BAFF)-stimulated cell proliferation and survival by suppressing Ca(2+)-CaMKII-dependent PTEN/Akt-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells. Cell Calcium. 2020;87:102171.
   PubMed Web of Science ®Google Scholar
• Zeng Q, Zhang H, Qin J, et al. Rapamycin inhibits BAFF-stimulated cell proliferation and survival by suppressing mTOR-mediated PP2A-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells. Cell Mol Life Sci. 2015;72:4867–4884.
   PubMed Web of Science ®Google Scholar
• Kraaijeveld R, Li Y, Yan L, et al. Inhibition of T helper cell differentiation by tacrolimus or sirolimus results in reduced B-cell activation: effects on T follicular helper cells. Transplant Proc. 2019;51:3463–3473.
   PubMed Web of Science ®Google Scholar
• Yu TS, Wang HY, Zhao YJ, et al. Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia. Blood Adv. 2021;5:4087–4101.
   PubMed Web of Science ®Google Scholar
• Semple JW. Bregging rights in ITP. Blood. 2012;120:3169.
   PubMed Web of Science ®Google Scholar
• Flores-Borja F, Bosma A, Ng D, et al. CD19+ CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med. 2013;5:173ra123.
   Web of Science ®Google Scholar
• Song J, Du G, Chen W, et al. The advantage of Sirolimus in amplifying regulatory B cells and regulatory T cells in liver transplant patients. Eur J Pharmacol. 2020;869:172872.
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhou Y, Wen J, et al. Circulating myeloid-derived suppressor cells predict disease activity and treatment response in patients with immune thrombocytopenia. Braz J Med Biol Res. 2017;50:e5637.
   PubMed Web of Science ®Google Scholar
• Hou Y, Xie J, Wang S, et al. Glucocorticoid receptor modulates myeloid-derived suppressor cell function via mitochondrial metabolism in immune thrombocytopenia. Cell Mol Immunol. 2022. doi:10.1038/s41423-41022-00859-41420.
   Web of Science ®Google Scholar
• Wang GY, Chen GH, Li H, et al. Rapamycin-treated mature dendritic cells have a unique cytokine secretion profile and impaired allostimulatory capacity. Transpl Int. 2009;22:1005–1016.
   PubMed Web of Science ®Google Scholar
• Turnquist HR, Cardinal J, Macedo C, et al. mTOR and GSK-3 shape the CD4+ T-cell stimulatory and differentiation capacity of myeloid DCs after exposure to LPS. Blood. 2010;115:4758–4769.
   PubMed Web of Science ®Google Scholar
• Borim PA, Mimura LAN, Zorzella-Pezavento SFG, et al. Effect of rapamycin on MOG-reactive immune cells and lipopolysaccharide-activated microglia: an in vitro approach for screening new therapies for multiple sclerosis. J Interferon Cytokine Res. 2022;42:153–160.
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang F, Zhang Z, et al. Everolimus ameliorates Helicobacter pylori infection-induced inflammation in gastric epithelial cells. Bioengineered. 2022;13:11361–11372.
   PubMed Web of Science ®Google Scholar
• Nguyen JH, Jiang LJ, Kang L, et al. Intranodal sirolimus induces regulatory T cells in human hepatic lymph nodes via interleukin 10 signaling. Liver Transpl. 2021;27:1669–1672.
   PubMed Web of Science ®Google Scholar
• Wise RM, Harrison MAA, Sullivan BN, et al. Short-term rapamycin preconditioning diminishes therapeutic efficacy of human adipose-derived stem cells in a murine model of multiple sclerosis. Cells. 2020;9.
   PubMed Web of Science ®Google Scholar
• Liu Z, Mei T. Immune thrombocytopenia induces autophagy and suppresses apoptosis in megakaryocytes. Mol Med Rep. 2018;18:4016–4022.
   PubMed Web of Science ®Google Scholar
• Wang CY, Ma S, Bi SJ, et al. Enhancing autophagy protects platelets in immune thrombocytopenia patients. Ann Transl Med. 2019;7:134.
   PubMed Web of Science ®Google Scholar
• Sun RJ, Shan NN. Megakaryocytic dysfunction in immune thrombocytopenia is linked to autophagy. Cancer Cell Int. 2019;19:59.
   PubMed Web of Science ®Google Scholar
• Guglieri-Lopez B, Perez-Pitarch A, Garcia-Cadenas I, et al. Effect of sirolimus exposure on the need for preemptive antiviral therapy for cytomeglovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25:1022–1030.
   PubMed Web of Science ®Google Scholar
• Taboada RG, Riechelmann RP, Mauro C, et al. Everolimus-induced pneumonitis in patients with neuroendocrine neoplasms: real-world study on risk factors and outcomes. Oncologist. 2022;27:97–103.
   PubMed Web of Science ®Google Scholar
• Chen X, Sun H, Cassady K, et al. The addition of sirolimus to GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation: a meta-analysis of efficacy and safety. Front Oncol. 2021;11:683263.
   PubMed Web of Science ®Google Scholar
• Hoff U, Markmann D, Nieminen-Kelha M, et al. Low-dose rapamycin does not impair vascular integrity and tubular regeneration after kidney transplantation in rats. Sci Rep. 2021;11:16270.
   PubMed Web of Science ®Google Scholar
• Hematopoietic Stem Cell Application Group CSoHCMA, China Association for the Prevention of Hematology D. Chinese consensus on the diagnosis and management of chronic graft-versus-host disease (2021). Zhonghua Xue Ye Xue Za Zhi. 2021;42:265–275.
   PubMedGoogle Scholar
• Nwaroh E, Jupp J, Jadusingh E, et al. Clinical impact and management of fluconazole discontinuation on sirolimus levels in bone marrow transplant patients. J Oncol Pharm Pract. 2018;24:235–238.
   PubMed Web of Science ®Google Scholar
• Gu H, Wu RH. Advance of mechanisms and clinical applications about rapamycin for treating immune mediated hemocytopenia – review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018;26:1836–1840.
   PubMedGoogle Scholar
• You T, Wang Q, Zhu L. Role of autophagy in megakaryocyte differentiation and platelet formation. Int J Physiol Pathophysiol Pharmacol. 2016;8:28–34.
   PubMedGoogle Scholar
• Xu Z, Chu M. Advances in immunosuppressive agents based on signal pathway. Front Pharmacol. 2022;13:917162.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang C, Zhang G, et al. Role of autophagy and mTOR signaling in neural differentiation of bone marrow mesenchymal stem cells. Cell Biol Int. 2014;38:1337–1343.
   PubMed Web of Science ®Google Scholar
• Huang Y, Chen M, Yang C, et al. Sirolimus is effective for refractory/relapsed/intolerant acquired pure red cell aplasia: results of a prospective single-institutional trial. Leukemia. 2022;36:1351–1360.
   PubMed Web of Science ®Google Scholar